Treatment of unoperable and chemorefractory primary and secondary liver malignancies with Yttrium-90 resin microspheres

Objectives Our purpose is to evaluate the efficiency of Y-90 resin microspheres in the treatment of unoperable and chemorefractory malignancies.

Methods 67 pts were treated by radioembolization.15 pts have multifocal HCC (22.38%).The etiology of secondary liver malignancies was 20 colorectal cancer (mCRC) (29.85%),12 neuroendocrine tumor (mNET) (17.91%),and 20 other (29,85%).Before radioembolization,the patients have been treated with surgery or other protocols.Median follow-up after radioembolization was 7 months (range3-18 months).CT,MRI,PET/CT,and Octreoscan were used for pre and post treatment follow-up.The median time for the first imaging follow-up was 2 months.

Results 67 pts with liver malignancies were evaluable.During follow-up, 34 pts died; 29 pts died of pimary disease and 5 pts died of non-cancerous causes.47 pts had regression,11 pts had stabile disease and 8 pts had progression at the first imaging follow-up.The median survival has not yet been reached,because 33 pts are still alive and their follow-up continues.15 pts with multifocal HCC were evaluable.6 pts are still alive and median followup after radioembolization is 6 months.8 pts died of primary disease (53.34%) and one patient died of noncancerous causes before the first imaging follow-up.10 pts had regression, 2 pts had stabile disease and 2 pts had progression.20 pts with mCRC were evaluable.9 pts are still alive and median follow-up after treatment is 7 months.9 pts died of primary disease (45%) and 2 pts died of noncancerous causes. 13 pts had regression,4 pts had stabile disease and 3 pts had progression.12 pts with mNET were evaluable.9 pts are still alive and median follow-up after treatment is 10 months.2 pts died of primary disease (16.67%).All pts had regression.

Conclusions Y-90 resin microspheres seems to be a safe and effective therapeutic option for the treatment of unoperable and chemorefractory liver malignancies which fail in currently available other treatments